PET评估肺部炎症的进展:一项系统综述
该系统综述检索了1995至2019年间的多个数据库,共纳入68篇文章并对其中的53篇进行叙述性合成,总结用于量化肺部炎症的新兴PET放射性示踪剂。由于研究人群异质、研究设计及图像采集和分析方法差异大,无法进行数据合并。结论指出目前从动物模型转化到人体研究的靶向肺部炎症的新型示踪剂很少,18F-FDG研究最广泛,虽非特异性炎症示踪剂,但多种肺部疾病的人体研究支持其作为炎症生物标志物使用。
要点
- 18F-FDG研究最广泛,虽非特异性炎症示踪剂,但多种肺部疾病的人体研究支持其作为炎症生物标志物。
- 能跨过从动物模型到人体研究转化鸿沟的靶向肺部炎症新型示踪剂目前很少。
- 18F-FDG肺部图像的最佳分析方法仍存争议,图像采集与分析的标准化应有助于提高研究结果的可信度。
核心结论
- 目前能跨过从动物模型到人体研究转化鸿沟的靶向肺部炎症新型放射性示踪剂很少,但结果突出显示了少量有前景、值得在人体中进一步评估的示踪剂。
- 18F-FDG研究最广泛,虽非特异性炎症示踪剂,但多种肺部疾病的人体研究支持其作为炎症生物标志物使用。
- 关于18F-FDG肺部图像的最佳分析方法仍存争议,图像采集与分析的标准化应有助于提高研究结果的可信度。
- PET放射性示踪剂可提供与分子通路活性相关的定量、靶向生物标志物,并可能加速特异性抗炎药物的开发。
研究设计与样本
- 系统综述,检索Medline、Embase、Scopus、PubMed、Web of Science和Cochrane数据库,纳入1995至2019年间使用PET放射性示踪剂评估肺部炎症反应的所有研究。
- 从共911篇涵盖动物和人体研究的文章中,由两名评审者根据纳入/排除标准筛选,最终从68篇选定文章中提取数据。
- 68篇中有53篇(包括人体和动物研究)符合合成条件;因研究人群异质及研究设计、图像采集和分析差异大,无法进行数据合并,故采用叙述性合成。
临床应用与阅片要点
- 18F-FDG虽非特异性炎症示踪剂,但多种肺部疾病的人体研究支持其作为炎症生物标志物使用。
- 关于18F-FDG肺部图像的最佳分析方法仍存争议,图像采集与分析的标准化应有助于提高研究结果的可信度。
- PET放射性示踪剂可提供与分子通路活性相关的定量、靶向生物标志物,并可能加速特异性抗炎药物的开发。
局限性
- 研究人群异质,研究设计、图像采集和分析存在差异,导致无法进行数据合并。
- 目前能跨过从动物模型到人体研究转化鸿沟的靶向肺部炎症新型放射性示踪剂很少。
- 结果突出显示的少量有前景示踪剂值得在人体中进一步评估。
- 关于18F-FDG肺部图像的最佳分析方法仍存争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Respiratory diseases are one of the leading causes of death worldwide, yet effective treatment options remain limited. Although inflammation is thought to be a key driver in the pathogenesis and progression of several lung diseases, the underlying molecular mechanisms of lung dysfunction remain poorly understood. Imaging techniques may help to further our understanding of the pathophysiology and facilitate the translation of novel therapies. Positron Emission Tomography (PET) is a functional imaging technique which has the potential to interrogate the underlying inflammatory response. We present a systematic review of the literature summarising the emerging PET radiotracers developed to quantify pulmonary inflammation.
METHOD: We performed a systematic review using the following databases: Medline, Embase, Scopus, PubMed, Web of Science and Cochrane. We included articles between 1995 and 2019 for all studies using PET radiotracers to evaluate inflammatory response in the lung. From a total of 911 articles covering both animal and human studies, two reviewers selected papers based on the inclusion/exclusion criteria and extracted data from 68 articles selected.
RESULTS: 53 out of 68 papers, including both human and animal studies, were eligible for synthesis. Heterogenous study populations and differences in study design, image acquisition and analysis made data pooling unfeasible; instead, we provide a narrative synthesis.
CONCLUSIONS: Currently, very few novel radiotracers targeting lung inflammation have crossed the translational gap from animal models to human studies. Nevertheless, our results highlight a handful of promising tracers which warrant further evaluation in humans. 18F-FDG has been investigated most extensively; although 18F-FDG is not a specific inflammatory tracer, human studies of several pulmonary diseases support its use as a biomarker for inflammation. Despite ongoing debate about the optimal analysis methodology for 18F-FDG lung images, standardisation of image acquisition and analysis should help to improve confidence in research outcomes. PET radiotracers can provide quantitative, targeted biomarkers which relate to the activity of molecular pathways and may expedite development of specific anti-inflammatory drugs.
引用
- Vass L, Fisk M, Lee S, et al. Advances in PET to assess pulmonary inflammation: A systematic review. Eur J Radiol. 2020. PMID: 32702614. doi:10.1016/j.ejrad.2020.109182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。